Opening a new pathway
for PAD patients
IsomAb is taking a different approach to identify, evaluate and develop isoform specific antibodies to treat disease where patients currently have limited or no treatment options.
Peripheral Arterial Disease (PAD) is known to affect over 200 million people globally; type 2 diabetes (T2D) is a leading risk factor for its development. It can result in ischaemic disease in many areas of the body, and in the lower limbs can progress to chronic limb threatening ischaemia (CLTI); a leading cause of amputation and increased mortality.
IsomAb’s therapeutic antibody, ISM-001, which specifically inhibits the VEGF-A165b isoform of Vascular Endothelial Growth Factor-A (VEGF-A) was identified based on 20 years of research by our two Founders.
ISM-001 would provide an unparalleled approach to treat patients with PAD and T2D.
